For research use only. Not for use in humans.

Oleclumab (Anti-NT5E / CD73)

Synonyms: NT5E, Ecto-5'-nucleotidase

Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD.

Oleclumab (Anti-NT5E / CD73)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A261101 Purity: 99% Protein concentration: 16.07mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD.
References

Product Details

CAS No. 1803176-05-7
Molecular Weight 143.14
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05061550 RECRUITING Drug: Durvalumab|Drug: Oleclumab|Drug: Monalizumab|Drug: Dat Non-small Cell Lung Cancer AstraZeneca 2022-04-14 PHASE2
NCT06984588 ACTIVE_NOT_RECRUITING Drug: Uliledlimab|Drug: Toripalimab|Drug: Pembrolizumab Non Small Cell Lung Cancer TJ Biopharma Co., Ltd. 2024-03-28 PHASE2; PHASE3
NCT07146230 NOT_YET_RECRUITING Drug: Durvalumab|Drug: Monalizumab|Drug: Oleclumab Non-small Cell Lung Cancer Montefiore Medical Center 2026-09 PHASE2
NCT04940286 ACTIVE_NOT_RECRUITING Drug: Gemcitabine|Drug: Nab-paclitaxel Borderline Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage IA Pancreatic Cancer AJCC v8; Stage IB Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8 M.D. Anderson Cancer Center 2021-09-28 PHASE2
NCT04668300 ACTIVE_NOT_RECRUITING Metastatic Angiosarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Osteosarcoma; Recurrent Angiosarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Osteosarcoma; Refractory Dedifferentiated Liposarcoma; Refractory Osteosarcoma M.D. Anderson Cancer Center 2020-11-26 PHASE2
NCT07333573 NOT_YET_RECRUITING Stage IV Gastric Cancer Shanghai Zhongshan Hospital 2026-01-01 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.